Track topics on Twitter Track topics that are important to you
Lonza has expanded its growing presence in mammalian manufacturing by acquiring a clinical-stage site in Hayward, CA, from Shire for an undisclosed price. The acquisition, completed yesterday, will add the Hayward site’s 1,000L and 2,000L single-use bioreactors and associated downstream capabilities to Lonza’s three 1,000L single-use bioreactors at its mammalian development and manufacturing site in Slough, UK, focused on preclinical to early clinical supply. “The site will significantly increase our single-use bioreactor capacity in the clinical development mammalian network,” Lonza spokeswoman Constance Ward told GEN. The 58,000-square-foot Hayward site has operated as a multiproduct cGMP facility since 1990. Shire inherited the Hayward site when it completed its $32 billion acquisition of Baxter spinout Baxalta in 2016 . “Shire continually reviews its product supply network to ensure we are operating efficiently and ready to meet the needs of our patients today and in the future. To this ...NEXT ARTICLE
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...